enhertu.com Open in urlscan Pro
20.50.139.246  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Select a Cancer Type
   * HER2+ Metastatic Breast Cancer
   * HER2-Low Metastatic Breast Cancer
   * HER2+ (IHC 3+) Metastatic Cancers
   * HER2-Mutant Metastatic Lung Cancer
   * HER2+ Advanced Stomach Cancer
 * Important Safety Information
 * Prescribing Information
 * Medication Guide
 * Healthcare Professional Site
 * Treatment Access

This site is intended for US residents 18 years of age or older.
 * Home
 * Understanding HER2-low mBC
 * About ENHERTU
 * Results With ENHERTU
 * Potential Side Effects
 * Support & Resources


 * SELECT A CANCER TYPE
   
   * HER2+ Metastatic Breast Cancer
   * HER2-Low Metastatic Breast Cancer
   * HER2+ (IHC 3+) Metastatic Cancers
   * HER2-Mutant Metastatic Lung Cancer
   * HER2+ Advanced Stomach Cancer

 * Home
 * Understanding HER2-low mBC
 * About ENHERTU
 * Results With ENHERTU
 * Potential Side Effects
 * Support & Resources
 * Sign Up for Information

 * Important Safety Information
 * Prescribing Information
 * Medication Guide
 * Healthcare Professional Site
 * Treatment Access
 * This site is intended for US residents 18 years of age or older.




UNDERSTANDING HER2-LOW MBC

 * About HER2-low mBC
 * Have questions about HER2?

Not an actual patient.


HER2-LOW (IHC 1+ OR IHC 2+/ISH−) METASTATIC BREAST CANCER IS MORE COMMON THAN
YOU MAY THINK

Not an actual patient.


HAVE QUESTIONS ABOUT HER2?


WHAT IS HER2?

HER2 is a protein that tells cells to grow. When cells produce too much HER2,
they can become cancerous


WHAT IS HER2-LOW?

Breast cancer used to be scored as either HER2-positive or HER2-negative. HER2
levels are measured based on a testing method called immunohistochemistry (IHC).
Scores range from IHC 0 (the lowest) to IHC 3+ (the highest). HER2-low (IHC 1+
or IHC 2+/ISH–)* is a possible HER2 status as well. Having HER2-low means that
there is a low level of HER2 on the cancer cells but not enough HER2 to be
considered HER2-positive

*In-situ hybridization (ISH), which is scored as either positive or negative, is
an additional test to further determine HER2 levels.


HOW COMMON IS HER2-LOW?

About 60% of people with HER2-negative breast cancer actually have low levels of
HER2 (IHC 1+ or IHC 2+/ISH–)


WHAT IS HR STATUS?

HER2 status is different than HR (hormone receptor) status. People with low
levels of HER2 can be either HR+ (hormone receptor-positive) or HR– (hormone
receptor-negative)

 * HR status is also referred to as ER+ or ER– (estrogen
   receptor-positive/negative) and/or PR+ or PR– (progesterone
   receptor-positive/negative)
 * If someone was previously told they are ER-, PR-, and HER2-negative, this is
   often called triple-negative breast cancer (TNBC). TNBC means that the tumor
   lacks three specific proteins: estrogen receptors, progesterone receptors,
   and HER2


SHOULD I ASK MY DOCTOR ABOUT MY HER2 STATUS?

If your healthcare provider told you that you have HER2-negative metastatic
breast cancer (mBC), ask if your HER2 IHC score could indicate a diagnosis of
HER2-low (IHC 1+ or IHC 2+/ISH–) mBC


IS ENHERTU RIGHT FOR ME?

If you do have HER2-low (IHC 1+ or IHC 2+/ISH-) mBC and have received a prior
chemotherapy for mBC, treatment with ENHERTU may be right for you

Financial support

Learn about ENHERTU4U

Would you like to receive updates about ENHERTU?

Sign up for information

HER2, human epidermal growth factor receptor 2.

Important Safety Information  

What is ENHERTU?
ENHERTU is a prescription medicine used to treat adults who have:

 * HER2-low breast cancer that cannot be removed by surgery or that has spread
   to other parts of your body (metastatic), and who have received a prior
   chemotherapy:
   * for metastatic disease, or 
   * your disease has returned during or within 6 months of completing adjuvant
     chemotherapy (after surgery). Your healthcare provider will perform a test
     to make sure ENHERTU is right for you.

It is not known if ENHERTU is safe and effective in children.

What is the most important information I should know about ENHERTU?
ENHERTU can cause serious side effects, including:
Lung problems that may be severe, life-threatening or that may lead to death. If
you develop lung problems your healthcare provider may treat you with
corticosteroid medicines. Tell your healthcare provider right away if you get
any of the following signs and symptoms:

 * Cough
 * Trouble breathing or shortness of breath
 * Fever
 * Other new or worsening breathing symptoms (such as chest tightness, wheezing)

Low white blood cell count (neutropenia). Low white blood cell counts are common
with ENHERTU and can sometimes be severe. Your healthcare provider will check
your white blood cell counts before starting ENHERTU and before starting each
dose. Tell your healthcare provider right away if you develop any signs or
symptoms of an infection or have fever or chills during treatment with ENHERTU.

Heart problems that may affect your heart's ability to pump blood. Your
healthcare provider will check your heart function before starting treatment
with ENHERTU. Tell your healthcare provider right away if you get any of the
following signs and symptoms:

 * New or worsening shortness of breath
 * Coughing
 * Feeling tired
 * Swelling of your ankles or legs

 * Irregular heartbeat
 * Sudden weight gain
 * Dizziness or feeling light-headed
 * Loss of consciousness

Your healthcare provider will check you for these side effects during your
treatment with ENHERTU. Your healthcare provider may reduce your dose, delay
treatment or completely stop treatment with ENHERTU if you have severe side
effects.

Harm to your unborn baby. Tell your healthcare provider right away if you become
pregnant or think you might be pregnant during treatment with ENHERTU.

 * If you are able to become pregnant, your healthcare provider should do a
   pregnancy test before you start treatment with ENHERTU.
 * Females who are able to become pregnant should use effective birth control
   (contraception) during treatment with ENHERTU and for 7 months after the last
   dose.
 * Males who have female partners that are able to become pregnant should use
   effective birth control (contraception) during treatment with ENHERTU and for
   4 months after the last dose.

Before you receive ENHERTU, tell your healthcare provider about all of your
medical conditions, including if you:

 * Have lung or breathing problems.
 * Have signs or symptoms of an infection.
 * Have or have had any heart problems.
 * Are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes
   into your breast milk. Do not breastfeed during treatment with ENHERTU and
   for 7 months after the last dose.

Tell your healthcare provider about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive ENHERTU?

 * You will receive ENHERTU into your vein through an intravenous (IV) line by
   your healthcare provider.
 * ENHERTU is given 1 time every three weeks (21-day treatment cycle).
 * Your healthcare provider will decide how many treatments you need.
 * Your healthcare provider will give you medicines before your infusion to help
   prevent nausea and vomiting.
 * Your healthcare provider may slow down or temporarily stop your infusion of
   ENHERTU if you have an infusion-related reaction, or permanently stop ENHERTU
   if you have severe infusion reactions.
 * If you miss a planned dose of ENHERTU, call your healthcare provider right
   away to schedule an appointment. Do not wait until the next planned treatment
   cycle.

What are the possible side effects of ENHERTU?

ENHERTU can cause serious side effects. See "What is the most important
information I should know about ENHERTU?"

The most common side effects of ENHERTU when used at the 5.4 mg/kg dose
include: 

 * Nausea
 * Low white blood cell counts 
 * Low red blood cell counts 
 * Feeling tired 
 * Low platelet counts 
 * Increased liver function tests 
 * Vomiting 

 * Hair loss 
 * Constipation 
 * Decreased appetite
 * Low levels of blood potassium
 * Diarrhea 
 * Muscle or bone pain 
 * Stomach-area pain 

ENHERTU may cause fertility problems in males, which may affect the ability to
father children. Talk to your healthcare provider if you have concerns about
fertility.

These are not all of the possible side effects of ENHERTU. Call your doctor for
medical advice about side effects. You may report side effects to Daiichi Sankyo
at 1-877-437-7763 or to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed
WARNINGS, and Medication Guide.

What is ENHERTU?
ENHERTU is a prescription medicine used to treat adults who have:

 * HER2-low breast cancer that cannot be removed by surgery or that has spread
   to other parts of your body (metastatic), and who have received a prior
   chemotherapy:
   * for metastatic disease, or 
   * your disease has returned during or within 6 months of completing adjuvant
     chemotherapy (after surgery). Your healthcare provider will perform a test
     to make sure ENHERTU is right for you.

It is not known if ENHERTU is safe and effective in children.

To contact us with questions or concerns about a Daiichi Sankyo product,
please call us: 1-877-4DS-PROD (1-877-437-7763).

To contact us with questions or concerns about a Daiichi Sankyo product, please
call us: 1-877-4DS-PROD (1-877-437-7763).

ENHERTU® is a registered trademark of Daiichi Sankyo Company, Limited.
© 2024 Daiichi Sankyo, Inc. and AstraZeneca. 
PP-US-ENB-3344 09/24

 * Prescribing Information
 * Contact Us
 * Privacy Policy
 * Site Map

 * Terms and Conditions
 * Important Safety Information
 * About Daiichi Sankyo